Loading
A family of red chemotherapy drugs derived from a soil bacterium that damage cancer DNA. Cornerstones of breast cancer, lymphoma, leukaemia and sarcoma treatment, but they weaken the heart in a dose-dependent way, so there is a lifetime limit.
Doxorubicin, epirubicin, daunorubicin and idarubicin intercalate DNA and poison topoisomerase II. They anchor AC/EC in breast cancer, CHOP in lymphoma, 7+3 in AML and doxorubicin-ifosfamide in sarcoma. Cumulative doses above about 450 mg/m² doxorubicin cause cardiomyopathy, and even lower doses matter in children and with trastuzumab, which motivates anthracycline-free regimens (TCHP, docetaxel-cyclophosphamide), dexrazoxane, liposomal formulations and cardiac surveillance. They also cause alopecia, myelosuppression, and secondary leukaemia (topoisomerase-related, 1-2%), and as ADC payloads they are being revisited.
Showing the molecule this term concerns: Doxorubicin.
The last major guideline written before KEYNOTE-522 changed the standard; the 2022 rapid update reversed the immunotherapy line within a year.
Chemotherapy works in receptor-negative disease at least as well as in receptor-positive disease in proportional terms, and because triple-negative absolute risk is high the absolute gain is large; this is why anthracycline and taxane backbone survived into KEYNOTE-522 and why SCARLET now asks whether the anthracycline can go.
Shares Neoadjuvant Chemotherapy, Endocrine Therapy, and Targeted Therapy for Breast Cancer: ASCO Guideline, Comparisons between different polychemotherapy regimens for early breast cancer: meta-analyses of long-term outcome among 100,000 women in 123 randomised trials, Triple-negative breast cancer roadmap: from a remainder defined by three negative tests to immunotherapy, antibody-drug conjugates and the residual disease problem, Cytotoxic chemotherapy.
Shares Strain echocardiography (global longitudinal strain), Troponin and natriuretic peptide monitoring during cancer treatment, Cardio-oncology, Doxorubicin.
Shares Cardio-oncology, Doxorubicin, Sarcomas (soft tissue, bone, GIST), Diffuse large B-cell lymphoma.
Shares Cardiotoxicity (LVEF decline, cardiomyopathy), Troponin and natriuretic peptide monitoring during cancer treatment, Cardio-oncology.
Shares Troponin and natriuretic peptide monitoring during cancer treatment, Cardio-oncology, Doxorubicin, Sarcomas (soft tissue, bone, GIST).
Shares Strain echocardiography (global longitudinal strain), Troponin and natriuretic peptide monitoring during cancer treatment, Cardio-oncology, Doxorubicin.
Shares Comparisons between different polychemotherapy regimens for early breast cancer: meta-analyses of long-term outcome among 100,000 women in 123 randomised trials, Give exceptional responders less: pembrolizumab omission after complete response, anthracycline-free regimens and chemotherapy omission in lymphocyte-rich stage I disease, Triple-negative breast cancer roadmap: from a remainder defined by three negative tests to immunotherapy, antibody-drug conjugates and the residual disease problem, Triple-negative breast cancer (TNBC).
Shares Strain echocardiography (global longitudinal strain), Troponin and natriuretic peptide monitoring during cancer treatment.